ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/cytidine-deaminase
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/cytidine-deaminase
6
trial(s) found.
NCT05636514
Haem
Phase 1
Recruiting
A Phase I Study of Oral Decitabine and Cedazuridine (ASTX727) In Combination With Defactinib (VS-6063) as Therapy of Myelodysplastic Syndromes and Low-blast Acute Myeloid Leukaemia (
CELESTIAL-MDS
)
DNA methyltransferase inhibitor
FAK inhibitor
cytidine deaminase inhibitor
Acute myeloid leukaemia
Chronic myelomonocytic leukaemia
Myelodysplastic syndrome
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
ACTRN12625000201471
Haem
Phase 1 / Phase 2
Not yet recruiting
ALLG MDS05 (MYDAS-T)/D3 (MESSAGE): Myelodysplasia Advancing Strategies in Therapy platform trial - Mesenchymal signal targeting in Myelodysplasia as a pathway to transfusion independence and blood count improvement (
MDS05-D3
)
Cedazuridine
DNA methyltransferase inhibitor
Decitabine
cancer therapy
cancer therapy,DNA methyltransferase-targeting
cancer therapy,cytidine deaminase-targeting
cytidine deaminase inhibitor
+ cancer therapy,cytidine deaminase-targeting
Solid tumour
ACTRN12622001302741
Haem
Phase 1 / Phase 2
Not yet recruiting
MDS05/D2 - A multicentre phase Ib/II open label randomized platform design study to determine the safety and efficacy of SRA515 and ASTX727 for treatment of intermediate and high risk Myelodysplastic Syndrome (MDS). (
ALLG
)
BRD4 inhibitor
cytidine deaminase inhibitor
Acute myeloid leukaemia
Myelodysplastic syndrome
ACTRN12621001713886
Haem
Phase 1 / Phase 2
Recruiting
MDS05/D1: (MYDAS-T) Assessing the safety of ES-3000 and ASTX727 in patients with myelodysplasia (
MYDAS-T-Run-ES-IN
)
cytidine deaminase inhibitor
Solid tumour
NT
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3168 - Clayton - Monash Medical Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT05883956
Haem
Phase 3
Active not recruiting
A Phase 3b, Randomized, Open-Label, Double Crossover Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Adult Patients With IPSS R Intermediate Myelodysplastic Syndrome, Low Blast Acute Myeloid Leukemia, IPSS Intermediate-2 or High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (
PREFER-HMA
)
DNA methyltransferase inhibitor
antimetabolite
cytidine deaminase inhibitor
Leukaemia
Myelodysplastic syndrome
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
3844 - Traralgon - Latrobe Regional Hospital
QLD
4217 - Benowa - Pindara Private Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5006 - North Adelaide - Adelaide Oncology and Haematology
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3210 - Hamilton - Waikato Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NZ.9016 - Dunedin - Dunedin Hospital
NCT05403450
Haem
Phase 1 / Phase 2
Active not recruiting
A Phase 1-2, Open-Label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Activity of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma (
ASTX660-03
)
DNA methyltransferase inhibitor
cytidine deaminase inhibitor
dual IAP inhibitor
Peripheral T-cell lymphoma
NSW
2139 - Concord - Concord Repatriation General Hospital
VIC
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (2)
Active not recruiting (2)
Not yet recruiting (1)
Recruitment Country and State
NSW (4)
VIC (3)
SA (2)
NT (1)
NZ (1)
QLD (1)
WA (1)
Phase
Phase 1 (1)
Phase 1 / Phase 2 (4)
Phase 3 (1)
Trial Type
Haem (6)
Cancer Therapy Class
DNA methyltransferase
100%
cytidine deaminase
100%
FAK
17%
IAP
17%
Facility
2139 - Concord - Concord Repatriation General Hospital (2)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (2)
3168 - Clayton - Monash Medical Centre (2)
2031 - Randwick - Prince of Wales Hospital (1)
2050 - Camperdown - Chris O'Brien Lifehouse (1)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (1)
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology (1)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (1)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (1)
3844 - Traralgon - Latrobe Regional Hospital (1)
4217 - Benowa - Pindara Private Hospital (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
5006 - North Adelaide - Adelaide Oncology and Haematology (1)
NZ.0622 - Takapuna - North Shore Hospital (1)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (1)
NZ.3210 - Hamilton - Waikato Hospital (1)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
NZ.9016 - Dunedin - Dunedin Hospital (1)
6009 - Nedlands - Linear Clinical Research (1)
Cancer Type
Cancer
Haematological malignancy
Leukaemia
Myelodysplastic syndrome
Myeloproliferative neoplasm
Acute myeloid leukaemia
Myeloid leukaemia
Solid tumour
Chronic myelomonocytic leukaemia
Myelodysplastic/Myeloproliferative disease
Lymphoma
Non-Hodgkin's lymphoma
Peripheral T-cell lymphoma
T-cell lymphoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy